Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2029 • 2019 ACR/ARP Annual Meeting
Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus
Huilin Zhang ¹ and Qing Zhang², ¹Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), ²Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic)
Background/Purpose: In recent years, accumulating evidences have demonstrated that increased cAMP response element modulator α (CREMα) which can inhibit IL-2 and induce IL-17A in CD4+…
Abstract Number: 2516 • 2019 ACR/ARP Annual Meeting
Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus
Serena Fasano¹, Luciana Pierro ¹, Alessia Borgia ¹, Melania Coscia ¹, Ranieri Formica ¹, antonella Riccardi ¹ and Francesco Ciccia ¹, ¹University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a relapsing-remitting course. Uncontrolled lupus flares might lead to organ damage. The routinely performed biomarkers…
Abstract Number: 2548 • 2019 ACR/ARP Annual Meeting
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity
Aikaterini Thanou¹, Cristina Arriens ², Teresa Aberle ¹, Heather Miller ¹, Lydia Mitchell ³, Stan Kamp ¹, Anca Askanase ⁴, Stavros Stavrakis ⁵, Judith James ² and Joan T. Merrill ⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Columbia University, New York, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…
Abstract Number: 2742 • 2019 ACR/ARP Annual Meeting
Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, H. Michael Belmont ⁴, Peter Izmirly ⁵, Chandra Mohan ⁶, Ting Zhang ⁷, The Accelerating Medicines Partnership ⁸ and Michelle Petri ⁹, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴New York University School of Medicine, Ney York, ⁵New York University School of Medicine, New York, ⁶University of Houston, Houston, ⁷Biomedical Engineering, University of Houston, Houston, TX, ⁸Multiple Organizations, USA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) complicates up to 60% of patients with systemic lupus erythematosus (SLE) and carries a high morbidity and mortality. The definitive diagnosis…
Abstract Number: 9 • 2019 ACR/ARP Annual Meeting
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Julian Torres Vazquez¹, Alejandro Corzo Cruz ², David Alberto Comoto Santacruz ² and Omar Eloy Muñoz Monroy ¹, ¹Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Distrito Federal, Mexico, ²Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10…
Abstract Number: 246 • 2019 ACR/ARP Annual Meeting
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Nnenna Ezeh¹, Trevor McKown ¹, Shivani Garg ¹ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients of color are more likely to have systemic lupus erythematosus (SLE) and a smoking history. Prior literature notes that both smoking and race…
Abstract Number: 683 • 2019 ACR/ARP Annual Meeting
Biologic Differences Between Type 1 and 2 Lupus
Megan Clowse¹, Jennifer Rogers ¹, Amanda Eudy ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹, Kai Sun ¹, Micah McClain ², Ephraim Tsalik ³, Chris Woods ², David Pisetsky ⁴, Prathyusha Bachali ⁵, Amrie Grammer ⁶, Michelle Catalina ⁵ and Peter Lipsky ⁷, ¹Duke University, Durham, ²Duke University & Duke Center for Applied Genomics & Precision Medicine, Durham, ³Duke University, Duke Center for Applied Genomics & Precision Medicine, Durham VA, Durham, ⁴Duke University, Durham VAMC, Durham, ⁵AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ⁶AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, ⁷AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: The manifestations of systemic lupus erythematosus (SLE) can be divided into categories according to a recently proposed model: a category of classic active autoimmune-driven…
Abstract Number: 944 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study
Richard Furie¹, Ian Bruce ², Thomas Dörner ³, Manuel Gustavo Leon ⁴, Piotr Leszczyński ⁵, Murray Urowitz ⁶, Birgit Haier ⁷, Claire Brittain ⁸, Jiajun Liu ⁹, Catherine Barbey ¹⁰ and Christian Stach ⁷, ¹Northwell Health, Great Neck, NY, ²University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Investigaciones Clínicas, Lima, Peru, ⁵Poznań University of Medical Sciences, Poznań, Poland, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹Biogen, Cambridge, MA, ¹⁰Biogen, Baar, Switzerland
Background/Purpose: Dapirolizumab pegol (DZP) is a polyethylene glycol-conjugated Fab’ fragment, which targets CD40 ligand and is in development for the treatment of systemic lupus erythematosus…
Abstract Number: 1104 • 2019 ACR/ARP Annual Meeting
Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study
Elizabeth Arkema¹, Marios Rossides ¹, Christopher Sjöwall ², Elisabet Svenungsson ³ and Julia Simard ⁴, ¹Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, ³Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Previous studies examining the relative risk (RR) associated with having a first degree relative (FDR) with systemic lupus erythematosus (SLE) were small and few…
Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Hironari Hanaoka¹, Jun Kikuchi ², Shuntaro Saito ¹, Hiroshi Takei ³, Kazuoto Hiramoto ¹, Tatsuhiro Oshige ¹, Noriyasu Seki ⁴, Hideto Tsujimoto ⁴, Yuko Kaneko ¹ and Tsutomu Takeuchi ⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Keio Universitiy School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Mitsubishi Tanabe Pharma Corporation Sohyaku, Tokyo, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…
Abstract Number: 1610 • 2019 ACR/ARP Annual Meeting
Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index
Alexandra Legge¹, Susan Kirkland ¹, Kenneth Rockwood ¹, Pantelis Andreou ¹, Sang-Cheol Bae ², Caroline Gordon ³, Juanita Romero-Diaz ⁴, Jorge Sanchez-Guerrero ⁵, Daniel J Wallace ⁶, Sasha Bernatsky ⁷, Ann E Clarke ⁸, Joan Merrill ⁹, Ellen M Ginzler ¹⁰, Paul Fortin ¹¹, Dafna Gladman ¹², Murray Urowitz ¹³, Ian Bruce ¹⁴, David A Isenberg ¹⁵, Anisur Rahman ¹⁶, Graciela Alarcón ¹⁷, Michelle Petri ¹⁸, Munther A Khamashta ¹⁹, MA Dooley ²⁰, Rosalind Ramsey-Goldman ²¹, Susan Manzi ²², Kristjan Steinsson ²³, Asad A Zoma ²⁴, Cynthia Aranow ²⁵, Meggan Mackay ²⁶, Guillermo Ruiz-Irastorza ²⁷, S Sam Lim ²⁸, Murat Inanc ²⁹, Ronald F Van Vollenhoven ³⁰, Andreas Jönsen ³¹, Ola Nived ³¹, Manuel Ramos-Casals ³², Diane Kamen ³³, Kenneth C Kalunian ³⁴, Soren Jacobsen ³⁵, Christine Peschken ³⁶, Anca Askanase ³⁷ and John G Hanly ¹, ¹Dalhousie University, Halifax, NS, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Birmingham, Birmingham, United Kingdom, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁵Toronto Western Hospital, Toronto, ON, Canada, ⁶Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Oklahoma Medical Research Foundation, Oklahoma City, ¹⁰State University of New York Downstate Medical Center, Brooklyn, NY, ¹¹Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁵Centre for Rheumatology, London, United Kingdom, ¹⁶University College London, London, United Kingdom, ¹⁷University of Alabama at Birmingham, Birmingham, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹King's College London School of Medicine, London, United Kingdom, ²⁰UnC Kidney Centre, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburg, PA, ²³Landspitali, University Hospital, Reykjavik, Iceland, ²⁴University of Glasgow, East Kilbride, United Kingdom, ²⁵Feinstein Institute for Medical Research, Manhasset, NY, ²⁶Feinstein Institute for Medical Research, New York, ²⁷Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁰Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³¹Lund University, Lund, Sweden, ³²Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁴UC San Diego School of Medicine, LaJolla, CA, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶University of Manitoba, Winnipeg, Canada, ³⁷Columbia University Medical Center, New York, NY
Background/Purpose: We previously constructed a frailty index (FI) as a measure of susceptibility to adverse outcomes among patients with systemic lupus erythematosus (SLE). In this…
Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Sarah Patterson¹, Laura Trupin ¹, Cristina Lanata ¹, Louise Murphy ², Wendy Hartogenesis ¹, Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…
Abstract Number: 2032 • 2019 ACR/ARP Annual Meeting
Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation
Goh Murayama¹, Asako Chiba ², Ayako Makiyama ³, Taiga Kuga ⁴, Ken Yamaji ⁴, Naoto Tamura ⁴ and Sachiko Miyake ², ¹Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Interferona (IFNa) is increased and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes…
Abstract Number: 2517 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS
Hakan Babaoglu¹, Jessica Li ², Daniel Goldman ³, Laurence Magder ⁴ and Michelle Petri ², ¹Gazi University School of Medicine, Ankara, Turkey, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a potential treat to target goal in systemic lupus erythematosus (SLE), has been found to correlate with…
Abstract Number: 2552 • 2019 ACR/ARP Annual Meeting
Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Sarah Gilman ¹, Deborah Levesque ², Carol Cummins ³, Daniel Wallace ⁴, Victoria Werth ⁵ and Patricia Davidson⁶, ¹Wayfinder Health Strategies, Washington, DC, ²Pro-Change Behavior Systems, Providence, RI, ³Pro-Change Behavior Systems, Inc.,, Providence, ⁴Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Lupus Foundation of America, Washington, DC
Background/Purpose: The Lupus Foundation of America is in Year 4 of a 6-year cooperative agreement with the Centers for Disease Control and Prevention to develop…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].